ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

Two Decades of Struggle

The Supreme Court judgment in the Novartis case is important as it vindicates the entire process leading to health safeguards being incorporated in the Indian Patents Act. The article discusses this process, from the General Agreement on Tariffs and Trade and popular mobilisation in India to the enactment of and amendments to the Act, in the backdrop of the judgment.

The judgment by the Supreme Court of India, denying the claim of a patent on the anti-leukaemia drug Glivec (imatinib) by the Swiss multi;national Novartis, is important at many levels. In this article we discuss, in the backdrop of the judgment, the long and protracted course leading to the enactment of the Indian Patents Act of 2005.

The Uruguay Round

Dear Reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here


To gain instant access to this article (download).

Pay INR 50.00

(Readers in India)

Pay $ 6.00

(Readers outside India)

Back to Top